Hereditary von Willebrand disease

This study tested a medicine called vonicog alfa (rVWF), sometimes given with another drug (ADVATE), to control bleeding in 47 children under 18 with severe von Willebrand disease. The treatment was given for 12-18 months, and doctors checked how well it stopped bleeding and if i…

This study tested a freeze-dried plasma product that can be mixed with water in 6 minutes, avoiding the long thaw time of standard plasma. It included 42 trauma patients with severe bleeding who needed blood transfusions. The goal was to see if faster plasma delivery could improv…

This study tested a medicine called wilate in 12 children under 6 years old with severe von Willebrand disease, a bleeding disorder. The goal was to see if regular infusions of wilate could prevent bleeding episodes over 12 months. Researchers measured how many bleeds occurred, h…

This study tested a pathogen-reduced version of cryoprecipitate, a blood product that helps blood clot, in 208 patients undergoing liver transplant or heart surgery. The goal was to see if having this product readily available could stop bleeding early and reduce the need for oth…

This completed phase 3 trial tested whether adding tranexamic acid to recombinant von Willebrand factor (rVWF) reduces postpartum hemorrhage better than rVWF alone in 20 pregnant women with von Willebrand disease. Participants received either the combination or rVWF alone at deli…

This early-stage trial tested a single injection of a new drug called BIVV001 in 6 adults with severe forms of von Willebrand disease (types 2N and 3). The goal was to see how the drug behaves in the body and whether it is safe. If results are promising, larger studies could foll…

This study tested a drug called rVWF (Vonvendi) in 38 children and adults with severe von Willebrand disease, a bleeding disorder. The goal was to see if regular use of the drug could reduce the number of spontaneous bleeding episodes over a year. Participants received treatment …

This study follows people with severe von Willebrand disease (VWD) to see how well different treatments work and how safe they are in everyday use. Researchers are tracking side effects and how the body responds to therapy given on demand, during surgery, or as regular prevention…

This study examined the DNA of 254 people to find genetic changes that might explain why some individuals have mildly low levels of von Willebrand factor, a protein important for blood clotting. Researchers used whole-exome sequencing to look for variants in known and new genes. …

This study looked at whether using a video capsule endoscopy (a small camera pill) along with standard scopes can better find the source of gut bleeding in people with von Willebrand disease. Researchers reviewed records of 50 patients who had gut bleeding between 2015 and 2017. …

This study looked at 257 emergency patients on ECMO (a heart-lung machine) to understand why many experience serious bleeding. Researchers measured how often bleeding occurred and checked for defects in von Willebrand factor, a key clotting protein. The goal is to find links betw…

This completed study aimed to understand the real-life experiences of people with von Willebrand disease, a common but often overlooked bleeding disorder. Over 600 adults from the UK, Ireland, and the US shared their stories through online surveys, one-on-one interviews, and a 30…